KalVista Pharmaceuticals, Inc.
KALV
$13.55
-$0.05-0.37%
NASDAQ
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -48.51M | -42.27M | -40.44M | -44.65M | -29.03M |
| Total Depreciation and Amortization | 229.00K | 227.00K | 224.00K | 219.00K | 207.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10.01M | 2.19M | 2.31M | 12.72M | 2.28M |
| Change in Net Operating Assets | 5.59M | 213.00K | -2.31M | 16.61M | -1.03M |
| Cash from Operations | -32.68M | -39.64M | -40.22M | -15.11M | -27.57M |
| Capital Expenditure | -24.00K | -108.00K | -21.00K | -15.00K | -19.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 8.54M | 48.78M | 37.18M | -126.17M | -6.68M |
| Cash from Investing | 8.52M | 48.67M | 37.16M | -126.19M | -6.70M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 56.54M | 295.00K | 3.00M | 96.98M | 284.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 95.23M | -- | -- | 53.12M | -- |
| Cash from Financing | 151.77M | 295.00K | 3.00M | 150.10M | 284.00K |
| Foreign Exchange rate Adjustments | -1.25M | 407.00K | 117.00K | -74.00K | -621.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 126.36M | 9.73M | 59.00K | 8.73M | -34.61M |